{
  "id": "5a67ade5b750ff445500000c",
  "type": "yesno",
  "question": "Does erythromycin increase risk of hypertrophic pyloric stenosis?",
  "ideal_answer": "Yes, post-natal erythromycin exposure is associated with increased risk of hypertrophic pyloric stenosis. The association is stronger when exposure occurs in the first 2 weeks of life.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
    "http://www.ncbi.nlm.nih.gov/pubmed/12100810",
    "http://www.ncbi.nlm.nih.gov/pubmed/12693559",
    "http://www.ncbi.nlm.nih.gov/pubmed/11562617",
    "http://www.ncbi.nlm.nih.gov/pubmed/25687145",
    "http://www.ncbi.nlm.nih.gov/pubmed/23558266"
  ],
  "snippets": [
    {
      "text": "Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: Macrolide antibiotics, erythromycin, in particular, have been linked to the development of infantile hypertrophic pyloric stenosis (IHPS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Overall, erythromycin exposure was significantly associated with development of IHPS [OR 2.45 (1.12-5.35), p\u00a0=\u00a00.02]. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data on erythromycin exposure in the first 14\u00a0days of life was extracted from 4/9 studies and identified a strong association between erythromycin exposure and subsequent development IHPS [OR 12.89 (7.67-2167), p\u00a0<\u00a00.00001].CONCLUSION: This study demonstrates a significant association between post-natal erythromycin exposure and development of IHPS, which seems stronger when exposure occurs in the first 2\u00a0weeks of life.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVE: Use of oral erythromycin in infants is associated with infantile hypertrophic pyloric stenosis (IHPS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25687145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Ingestion of oral azithromycin and erythromycin places young infants at increased risk of developing IHPS.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25687145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An association between erythromycin and IHPS was also confirmed. Exposure to erythromycin in the first 14 days of life had an aOR of 13.3 (95% CI, 6.80-25.9), and 15 to 42 days of life, aOR 4.10 (95% CI, 1.69-9.91). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25687145",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early exposure to oral erythromycin in young infants, particularly in the first 2 weeks of life, has previously been associated with the development of hypertrophic pyloric stenosis. We report a case of an infant who received an abbreviated 4-day course of oral erythromycin for suspected Chlamydia conjunctivitis at 5 days of life then underwent pyloromyotomy for pyloric stenosis less than 2 weeks later.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23558266",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11562617",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A case report has suggested that exposure to erythromycin through breast milk might cause infantile hypertrophic pyloric stenosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Macrolide antibiotics, erythromycin, in particular, have been linked to the development of infantile hypertrophic pyloric stenosis (IHPS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Infants prescribed systemic erythromycin had increased risk of IHPS, with the highest risk in the first 2 weeks of age (relative risk = 10.51 for erythromycin in first 2 weeks, 95% CI 4.48, 24.66).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11562617",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was an association between maternal prescriptions for nonerythromycin macrolides and infantile hypertrophic pyloric stenosis (adjusted odds ratio 2.77, 95% confidence interval 1.22, 6.30, P =.01).<br><b>CONCLUSION</b>: The hypothesized association between erythromycin and infantile pyloric stenosis was not seen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12100810",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Macrolide antibiotics, erythromycin, in particular, have been linked to the development of infantile hypertrophic pyloric stenosis (IHPS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D046248",
    "https://meshb.nlm.nih.gov/record/ui?ui=D012306",
    "https://meshb.nlm.nih.gov/record/ui?ui=D004917"
  ],
  "exact_answer": "Yes"
}